Icon

DANOCRINE (nda017557)- (50MG,100MG,200MG)

DANAZOL SANOFI AVENTIS US
50MG,100MG,200MG
No No
Expired Expired
None None
None No
DANOCRINE is indicated for the treatment of endometriosis amenable to hormonal management. Most cases of symptomatic fibrocystic breast disease may be treated by simple measures (e.g., padded brassieres and analgesics). DANOCRINE is indicated for the prevention of attacks of angioedema of all types (cutaneous, abdominal, laryngeal) in males and females.
3 0 2
Total Other Developers None
Drugs with Suitability No
50MG ** ** - - -
100MG ** ** - - 2
200MG ** ** - - 2
NDA Sales Available Total Generic Sales Available
No 2
ANDA No Generic Co Manufacturer Name Operations Manufacturer Address Country
****** ******* ******* *******, ***. *********** **** * *** *, *******, ******* (**) *****, ****** ****** (***) ***
****** ******* ** *** ******* *******, ***. *********** **** * *** *, *******, ******* (**) *****, ****** ****** (***) ***

Download GenUS Drug Report


Download GenUS Detailed Report


To get detailed report Contact Us

GenUs Advanced Search




Expired
to
Expired
to


Brand Name Generic Name Strength Dosage Route of Administration Innovator ParaIV

Please contact contact@researchdelta.com to get more details.